Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009

Administered by Department of Veterans' Affairs

Legislation au F2009L04040 Not in force Legislative Instrument

Legislation content

Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009

made under subsection 196B(2) of the

Veterans' Entitlements Act 1986

Compilation No. 2  

Compilation date:   18 September 2017

Includes amendments up to: Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017) (F2017L01067)

The day of commencement of this Amendment Determination is 18 September 2017.

 

About this compilation

 

This compilation

This is a compilation of the Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009 that shows the text of the law as amended and in force on 18 September 2017.

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Selfrepealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

 

 

 

 

 

 

 

Statement of Principles

concerning

 

MALIGNANT NEOPLASM OF THE OVARY

No. 70 of 2009

 

for the purposes of the

 

Veterans’ Entitlements Act 1986

and

Military Rehabilitation and Compensation Act 2004

 

Title

1. This Instrument may be cited as Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009.

 

Determination

2. The Repatriation Medical Authority under subsection 196B(2) and (8) of the Veterans’ Entitlements Act 1986 (the VEA):

(a) revokes Instrument No. 43 of 1997 concerning malignant neoplasm of the ovary; and

(b) determines in its place this Statement of Principles.

 

Kind of injury, disease or death

3. (a) This Statement of Principles is about malignant neoplasm of the ovary and death from malignant neoplasm of the ovary.

(b)               For the purposes of this Statement of Principles, "malignant neoplasm of the ovary" means a primary malignant neoplasm arising from the cells of the ovary and including cell types of borderline malignant potential.  This definition excludes soft tissue sarcoma, carcinoid tumour, non-Hodgkin’s lymphoma and Hodgkin’s lymphoma.

(c)                Malignant neoplasm of the ovary attracts ICD-10-AM code C56 or D39.1.

(d)              In the application of this Statement of Principles, the definition of "malignant neoplasm of the ovary" is that given at paragraph 3(b) above.

 

Basis for determining the factors

4. The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that malignant neoplasm of the ovary and death from malignant neoplasm of the ovary can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the Military Rehabilitation and Compensation Act 2004 (the MRCA).

 

Factors that must be related to service

5. Subject to clause 7, at least one of the factors set out in clause 6 must be related to the relevant service rendered by the person.

 

Factors

6. The factor that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the ovary or death from malignant neoplasm of the ovary with the circumstances of a person’s relevant service is:

 

(a)                for epithelial ovarian cancer only,

(i)                 being nulliparous at the time of the clinical onset of malignant neoplasm of the ovary; or

(ii)               having hormone replacement therapy for at least five consecutive years before the clinical onset of malignant neoplasm of the ovary, and where the use of hormone replacement therapy has ceased, the clinical onset of malignant neoplasm of the ovary has occurred within ten years of that period; or

 

(b)               being obese for at least five years before the clinical onset of malignant neoplasm of the ovary; or

 

(c)                for mucinous ovarian tumours only, smoking at least five pack years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of malignant neoplasm of the ovary; or

 

(d)               an inability to undertake any physical activity greater than three METs for at least ten consecutive years within the 30 years before the clinical onset of malignant neoplasm of the ovary; or

 

(e)                an inability to consume at least 400 grams of vegetables per week for a period of at least five consecutive years within the 25 years before the clinical onset of malignant neoplasm of the ovary; or

 

(f)                applying talc to the perineal area on more days than not, for a period of at least five years, before the clinical onset of malignant neoplasm of the ovary; or

 

(g)               inhaling respirable asbestos fibres in an enclosed space for a cumulative period of at least 2000 hours before the clinical onset of malignant neoplasm of the ovary:

(i)                 at the time material containing asbestos fibres was being applied, removed, dislodged, cut or drilled; and

(ii)               the first inhalation of asbestos fibres commenced at least ten years,

before the clinical onset of malignant neoplasm of the ovary; or

 

(h)               having endometriosis for at least five years before the clinical onset of malignant neoplasm of the ovary; or

 

(i)                 having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the ovary at least five years before the clinical onset of malignant neoplasm of the ovary; or

 

(j)                 inability to obtain appropriate clinical management for malignant neoplasm of the ovary.

 

Factors that apply only to material contribution or aggravation

7. Paragraph 6(j) applies only to material contribution to, or aggravation of, malignant neoplasm of the ovary where the person’s malignant neoplasm of the ovary was suffered or contracted before or during (but not arising out of) the person’s relevant service.

 

Inclusion of Statements of Principles

8. In this Statement of Principles if a relevant factor applies and that factor includes an injury or disease in respect of which there is a Statement of Principles then the factors in that last mentioned Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

 

Other definitions

9. For the purposes of this Statement of Principles:

 

"being obese" means an increase in body weight by way of fat accumulation which results in a Body Mass Index (BMI) of thirty or greater.

The BMI = W/H2 and where:

W is the person's weight in kilograms and

H is the person's height in metres;

"cumulative equivalent dose" means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017;

Note 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.

Note 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.

 

"death from malignant neoplasm of the ovary" in relation to a person includes death from a terminal event or condition that was contributed to by the person’s malignant neoplasm of the ovary;

 

"hormone replacement therapy" means administration of oestrogen preparations often in combination with progesterone to offset a hormone deficiency following surgically induced or naturally occurring menopause;

 

"ICD-10-AM code" means a number assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM), Sixth Edition, effective date of 1 July 2008, copyrighted by the National Centre for Classification in Health, Sydney, NSW, and having ISBN 978 1 74210 016 6;

 

"MET" means a unit of measurement of the level of physical exertion.  1 MET = 3.5 ml of oxygen/kg of body weight per minute or, 1.0 kcal/kg of body weight per hour, or resting metabolic rate;

 

"nulliparous" means never having experienced a gestation period of at least 20 weeks;

 

"pack years of cigarettes, or the equivalent thereof in other tobacco products" means a calculation of consumption where one pack year of cigarettes equals twenty tailor made cigarettes per day for a period of one calendar year, or 7300 cigarettes. One tailor made cigarette approximates one gram of tobacco or one gram of cigar or pipe tobacco by weight. One pack year of tailor made cigarettes equates to 7300 cigarettes, or 7.3 kg of smoking tobacco by weight. Tobacco products means either cigarettes, pipe tobacco or cigars smoked, alone or in any combination;

 

"relevant service" means:

(a) operational service under the VEA;

(b) peacekeeping service under the VEA;

(c)                hazardous service under the VEA;

(d)               warlike service under the MRCA; or

(e)                non-warlike service under the MRCA;

 

"terminal event" means the proximate or ultimate cause of death and includes:

(a) pneumonia;

(b) respiratory failure;

(c) cardiac arrest;

(d) circulatory failure; or

(e)                cessation of brain function.

 

Application

10. This Instrument applies to all matters to which section 120A of the VEA or section 338 of the MRCA applies.

 

Date of effect

11. This Instrument takes effect from 11 November 2009.

 

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history. 

Endnote 2—Abbreviation key

 

o = order(s)

ad = added or inserted

Ord = Ordinance

am = amended

orig = original

amdt = amendment

par = paragraph(s)/subparagraph(s)

c = clause(s)

    /subsubparagraph(s)

C[x] = Compilation No. x

pres = present

Ch = Chapter(s)

prev = previous

def = definition(s)

(prev…) = previously

Dict = Dictionary

Pt = Part(s)

disallowed = disallowed by Parliament

r = regulation(s)/rule(s)

Div = Division(s)

 

exp = expires/expired or ceases/ceased to have

reloc = relocated

    effect

renum = renumbered

F = Federal Register of Legislation

rep = repealed

gaz = gazette

rs = repealed and substituted

LA = Legislation Act 2003

s = section(s)/subsection(s)

LIA = Legislative Instruments Act 2003

Sch = Schedule(s)

(md) = misdescribed amendment can be given

Sdiv = Subdivision(s)

    effect

SLI = Select Legislative Instrument

(md not incorp) = misdescribed amendment

SR = Statutory Rules

    cannot be given effect

SubCh = SubChapter(s)

mod = modified/modification

SubPt = Subpart(s)

No. = Number(s)

underlining = whole or part not

 

    commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009

 

2 November 2009

 

F2009L04040

11 November 2011

 

 

Amendment Statement of Principles concerning malignant neoplasm of the ovary No. 61 of 2011

 

18 May 2011

 

F2011L00793

 

25 May 2011

 

 

Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017)

 

22 August 2017

 

F2017L01067

 

18 September 2017

 

 

 

Endnote 4—Amendment history

 

Provision affected

How affected

Clause 6(i)……………...

rs. Instrument  No. 61 of 2011

Clause 6(j)……………...

rep. Instrument  No. 61 of 2011

Clause 7 – '6(k)………..'

am. Instrument  No. 61 of 2011

Clause 9 – ' "cumulative equivalent dose"……'

rs. Instrument  No. 61 of 2011

Clause 9 – ' "atomic radiation"…………….'

rep. Instrument  No. 61 of 2011

Clause 9 – ' "cumulative equivalent dose"……'

rs. Instrument  No. 58 of 2017

 

 

Overview

The Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009 was enacted to address the issue of malignant neoplasm of the ovary and death from such neoplasm in the context of veterans' entitlements and military rehabilitation. This legislative instrument, made under subsection 196B(2) of the Veterans' Entitlements Act 1986, was determined by the Repatriation Medical Authority and serves to replace the previous Statement of Principles No. 43 of 1997. The primary aim of this legislation is to establish a sound medical-scientific basis for linking malignant neoplasm of the ovary with the service of veterans, members of Peacekeeping Forces, or members of the Australian Defence Force under the Veterans' Entitlements Act 1986, or members under the Military Rehabilitation and Compensation Act 2004. This Statement of Principles outlines specific factors that, if present, indicate a reasonable hypothesis connecting the disease with the individual's service, thereby potentially qualifying them for veterans' entitlements and compensation. The Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009 came into effect on 11 November 2009, and it applies to all matters governed by section 120A of the Veterans' Entitlements Act 1986 or section 338 of the Military Rehabilitation and Compensation Act 2004. It provides definitions and criteria for assessing the relationship between the disease and the individual's service, aiming to ensure that those who have served and are affected by malignant neoplasm of the ovary can receive the appropriate support and compensation. This legislation reflects the commitment to recognising and addressing the health impacts on veterans and military personnel, facilitating their access to necessary entitlements and care.

Scope and Application

The Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009 applies to veterans, members of Peacekeeping Forces, or members of the Forces under the Veterans' Entitlements Act 1986 (VEA), as well as members under the Military Rehabilitation and Compensation Act 2004 (MRCA). It relates to claims concerning malignant neoplasm of the ovary and death from malignant neoplasm of the ovary, specifically when these conditions can be connected to relevant service rendered by the aforementioned individuals. The Act provides criteria for determining whether a reasonable hypothesis exists that connects the specified conditions with the service of these individuals, including factors such as nulliparity, hormone replacement therapy, obesity, smoking, physical inactivity, dietary habits, talc use, asbestos exposure, endometriosis, ionising radiation exposure, and inability to obtain appropriate clinical management. The Statement of Principles aims to assist in the assessment of claims for benefits or compensation related to malignant neoplasm of the ovary and its consequences. The Act came into effect on 11 November 2009 and has been subject to amendments, the latest being the Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017), which came into effect on 18 September 2017. The Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009 applies to all matters to which section 120A of the VEA or section 338 of the MRCA applies. It serves to provide a framework for determining whether a reasonable hypothesis exists that links the development of malignant neoplasm of the ovary or death from malignant neoplasm of the ovary with the relevant service of veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, as well as members under the MRCA. The factors outlined in the Statement of Principles include a range of conditions and exposures that, if present, can contribute to the development of the specified conditions. The application of this Statement of Principles is crucial for assessing claims for benefits or compensation related to malignant neoplasm of the ovary and its consequences, ensuring that the claims are evaluated in light of the individual's service history and the factors that may have contributed to their condition.

Key Provisions

The Statement of Principles concerning malignant neoplasm of the ovary No. 70 of 2009 (the Statement of Principles) is a legislative instrument made under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). It outlines the criteria for the Repatriation Medical Authority (RMA) to determine whether a malignant neoplasm of the ovary or death from such a neoplasm is related to the relevant service of veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA. The Statement of Principles revokes the previous Instrument No. 43 of 1997 and sets out new principles to be applied in determining the service-relatedness of malignant neoplasm of the ovary and related deaths. The Statement of Principles imposes several obligations on the parties involved. It requires the RMA to consider whether at least one of the listed factors (such as being nulliparous at the time of clinical onset, having used hormone replacement therapy, or having inhaled respirable asbestos fibres) must be related to the relevant service of the individual. If a relevant factor applies and includes an injury or disease for which there is an existing Statement of Principles, then the factors in that Statement of Principles also apply. The Statement of Principles applies to all matters to which section 120A of the VEA or section 338 of the MRCA applies and has been in effect since 11 November 2009. Any breaches of the provisions in this Statement of Principles could potentially lead to civil or criminal consequences, depending on the context in which they occur. However, the Statement of Principles itself does not explicitly outline specific offences, penalties, or consequences for breach. It is likely that any breaches would be addressed under the broader provisions of the VEA or MRCA, which may include fines, imprisonment, or other penalties as stipulated in those Acts. The maximum penalties would depend on the specific nature of the breach and the relevant provisions of the VEA or MRCA.

Legal classification tags

Area of Law
Veterans' Affairs
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.